198 related articles for article (PubMed ID: 35783014)
21. Identification and Validation of an Energy Metabolism-Related lncRNA-mRNA Signature for Lower-Grade Glioma.
Zhao J; Wang L; Wei B
Biomed Res Int; 2020; 2020():3708231. PubMed ID: 32802843
[TBL] [Abstract][Full Text] [Related]
22. RGS16 promotes glioma progression and serves as a prognostic factor.
Huang R; Li G; Zhao Z; Zeng F; Zhang K; Liu Y; Wang K; Hu H
CNS Neurosci Ther; 2020 Aug; 26(8):791-803. PubMed ID: 32319728
[TBL] [Abstract][Full Text] [Related]
23. Molecular and clinical features of a potential immunotherapy target ELK3 in glioma.
Xu H; Zhang L; Gao J; Wang J; Wang Y; Xiao D; Chai S
Medicine (Baltimore); 2022 Jul; 101(30):e29544. PubMed ID: 35905257
[TBL] [Abstract][Full Text] [Related]
24. The relationship between PLOD1 expression level and glioma prognosis investigated using public databases.
Tian L; Zhou H; Wang G; Wang WY; Li Y; Xue X
PeerJ; 2021; 9():e11422. PubMed ID: 34040895
[TBL] [Abstract][Full Text] [Related]
25. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
Hu Y; Tu Z; Lei K; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
[TBL] [Abstract][Full Text] [Related]
26. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
27. Identification of Hub Gene GRIN1 Correlated with Histological Grade and Prognosis of Glioma by Weighted Gene Coexpression Network Analysis.
Yang A; Wang X; Hu Y; Shang C; Hong Y
Biomed Res Int; 2021; 2021():4542995. PubMed ID: 34840971
[TBL] [Abstract][Full Text] [Related]
28. Nuclear FABP7 regulates cell proliferation of wild-type IDH1 glioma through caveolae formation.
Kagawa Y; Umaru BA; Kanamori M; Zama R; Shil SK; Miyazaki H; Kobayashi S; Wannakul T; Yang S; Tominaga T; Owada Y
Mol Oncol; 2022 Jan; 16(1):289-306. PubMed ID: 34716958
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas.
Hou C; Ishi Y; Motegi H; Okamoto M; Ou Y; Chen J; Yamaguchi S
J Neurooncol; 2019 Nov; 145(2):201-210. PubMed ID: 31506754
[TBL] [Abstract][Full Text] [Related]
31. Integrated profiling identifies caveolae-associated protein 1 as a prognostic biomarker of malignancy in glioblastoma patients.
Guo Q; Guan GF; Cheng W; Zou CY; Zhu C; Cheng P; Wu AH
CNS Neurosci Ther; 2019 Mar; 25(3):343-354. PubMed ID: 30311408
[TBL] [Abstract][Full Text] [Related]
32. N6-methyladenine-related genes affect biological behavior and the prognosis of glioma.
Qu S; Chen Z; Liu B; Liu J; Wang H
Cancer Med; 2021 Jan; 10(1):98-108. PubMed ID: 33264518
[TBL] [Abstract][Full Text] [Related]
33. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
34. Identification and validation of an ECM organization-related gene signature as a prognostic biomarker and therapeutic target for glioma patients.
Zhong Q; Zhong Q; Cai X; Wu R
Genes Genomics; 2023 Sep; 45(9):1211-1226. PubMed ID: 37301776
[TBL] [Abstract][Full Text] [Related]
35. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining.
Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ
World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437
[TBL] [Abstract][Full Text] [Related]
36. Significantly high expression of NUP37 leads to poor prognosis of glioma patients by promoting the proliferation of glioma cells.
Liu Z; Wang H; Jia Y; Wang J; Wang Y; Bian L; Liu B; Lian X; Zhang B; Ren Z; Zhang W; Dai W; Gao Y
Cancer Med; 2021 Aug; 10(15):5218-5234. PubMed ID: 34264013
[TBL] [Abstract][Full Text] [Related]
37. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
38. Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma.
Yan C; Wang J; Yang Y; Ma W; Chen X
J Cell Mol Med; 2019 Aug; 23(8):4876-4882. PubMed ID: 31210419
[TBL] [Abstract][Full Text] [Related]
39. Identification and validation of a five-lncRNA prognostic signature related to Glioma using bioinformatics analysis.
Zhang C; Liu H; Xu P; Tan Y; Xu Y; Wang L; Liu B; Chen Q; Tian D
BMC Cancer; 2021 Mar; 21(1):251. PubMed ID: 33750353
[TBL] [Abstract][Full Text] [Related]
40. CPLX2 is a novel tumor suppressor and improves the prognosis in glioma.
Chen Y; Ning J; Shu L; Wen L; Yan B; Wang Z; Hu J; Zhou X; Tao Y; Xia X; Huang J
J Neurooncol; 2024 Mar; 167(1):63-74. PubMed ID: 38427133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
